Gilead Sciences Inc (GILD)

65.55
0.00(0.00%)
  • Volume:
    100
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    62.30 - 62.30
  • Type:Equity
  • Market:Chile
  • ISIN:US3755581036

GILD Overview

Prev. Close
65.55
Day's Range
62.3-62.3
Revenue
-
Open
62.3
52 wk Range
62.3-72.53
EPS
-
Volume
100
Market Cap
79.36B
Dividend (Yield)
2.92
(4.45%)
Average Volume (3m)
100
P/E Ratio
-
Beta
-
1-Year Change
0%
Shares Outstanding
1,254,313,448
Next Earnings Date
26 Jul 2022
What is your sentiment on Gilead?
or
Market is currently closed. Voting is open during market hours.

Gilead Sciences Inc News

Gilead Sciences Inc Analysis

Gilead Sciences Inc Company Profile

Gilead Sciences Inc Company Profile

Employees
14400

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Read More

Technical Summary

Type
Daily
Weekly
Monthly
Moving Averages
Technical Indicators
Summary
  • Good job GILD. bullish move forward
    0
    • Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
      1
      • Up Again
        0
        • Time to load up before the big rise coming next week
          3
          • Classic pump n’ dump. What a shambles
            1
            • Will reach above 95
              5
              • when? hahah
                0
            • Good time to accumulate.
              1
              • Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
                2
                • High chance to be trading above 90, good long stock
                  4
                  • By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
                    3